Sica Domenic A
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA.
J Clin Hypertens (Greenwich). 2006 Jan;8(1):53-6. doi: 10.1111/j.1524-6175.2005.04140.x.
As a drug class, calcium channel blockers encompass a heterogeneous group of compounds with distinctive structures and pharmacologic characteristics. These agents are widely used in the treatment of hypertension, chronic coronary ischemia, and/or supraventricular arrhythmias. Much of the early debate alluding to increased cardiovascular risk associated with calcium channel blocker use has been silenced by an array of outcomes trials that show these drugs to be both safe and effective in reducing hard cardiovascular end points. The most common side effects associated with calcium channel blockers are vasodilatory in nature and include a non-volume-dependent form of peripheral edema, flushing, and headache. Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control.
作为一类药物，钙通道阻滞剂包含一组结构和药理特性各异的化合物。这些药物广泛用于治疗高血压、慢性冠状动脉缺血和/或室上性心律失常。早期许多关于使用钙通道阻滞剂会增加心血管风险的争论，已被一系列结果试验平息，这些试验表明这些药物在降低严重心血管终点方面既安全又有效。与钙通道阻滞剂相关的最常见副作用本质上是血管舒张性的，包括非容量依赖性外周水肿、潮红和头痛。尽管钙通道阻滞剂治疗有时会出现令人不适的副作用，但其强大的降压作用使其成为大多数用于控制血压的多药治疗方案的重要组成部分。
